New asthma drug aims to stop attacks before they start

NCT ID NCT07456033

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether depemokimab, an injected biologic drug, can reduce severe asthma attacks and help patients achieve remission when added to standard care. About 456 adults and adolescents with type 2 asthma at risk of flare-ups will receive either depemokimab or a placebo for up to 156 weeks. The main goal is to see if the drug lowers the number of attacks needing steroids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Depemokimab (a biologic drug given by injection)
What this could lead to: If successful, depemokimab could become a new add-on treatment to help people with type 2 asthma have fewer severe attacks and achieve long-term symptom control.
What could go wrong: This is an early-phase 3b/4 study, so results are not yet known. The drug may not work better than placebo, and side effects are possible. It is not a cure and requires ongoing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Newport Beach, California, 92663, United States
GSK Investigational Site
RECRUITING

Aventura, Florida, 33180, United States
GSK Investigational Site
RECRUITING

Kissimmee, Florida, 34746, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33135, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33144, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33173, United States
GSK Investigational Site
RECRUITING

Oklahoma City, Oklahoma, 73112, United States
GSK Investigational Site
RECRUITING

Rapid City, South Dakota, 57702, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.